Furthermore, while all the mice in the control group died before 40 days, most of the mice in the CD19 CAR T group survived for more than 70 days (Figure 1c), suggesting that CD19 CAR T-cell immunotherapy could increase the survival rate of mice with CD19+ tumor cells. The gene discussed is CD19; the disease is neoplasm.